ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

Clinical trial NCT07198724 · RECRUITING

Trial details

NCT number: NCT07198724
Sponsor: Kristina A. Fanucci
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Metastatic Breast Cancer HER2 Low Breast Carcinoma HER2-negative Breast Cancer Breast Cancer Breast Cancer Female

Start date: 2025-11-17
Primary completion: 2028-06-01
Enrollment: 65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.